Document Detail


Perimount pericardial bioprosthesis for aortic calcified stenosis: 18-year experience with 1133 patients.
MedLine Citation:
PMID:  17152784     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND AIM OF THE STUDY: Aortic stenosis (AS) is the most important cause of aortic valve disease, its prevalence increasing with patient age. The present study formed part of a long-term evaluation on use of the Perimount pericardial valve for aortic calcified stenosis. METHODS: A total of 1133 consecutive patients who underwent aortic valve replacement (AVR) with a Perimount pericardial bioprosthesis for degenerative AS between July 1984 and December 2003 at the authors' institution, was followed up in 2004. Among the patients (716 males, 417 females; mean age 72.6 years), 997 were in sinus rhythm, and the mean NYHA functional class was 2.3. Preoperative echocardiography indicated a mean gradient of 56 mmHg, a peak gradient of 89 mmHg, and an effective orifice area of 0.6 cm2. Associated procedures were required in 336 patients. RESULTS: All patients but 18 (1.5%) were followed up for an average of 5.5 years postoperatively; thus, the total follow up was 6,180 patient-years. Operative mortality was 2.8% (n=32), and there were 330 late deaths. At 18 years the actuarial survival rate was 22 +/- 4%. Among the 725 patients followed, 80% were in sinus rhythm and 98% in NYHA classes I or II. Valve-related complications included 39 thromboembolic episodes, 24 endocarditis, 22 anticoagulant-related hemorrhage, 28 reoperations, and 19 structural valve failures. A total of 54 patients died from valve-related causes (13 embolic events, two endocarditis, two hemorrhage, one structural failure, 36 unknown causes), and 57 died from cardiac failure. Neither thrombosis nor hemolysis was observed. At 18 years, freedom from embolism was 92 +/- 2%, from endocarditis 93 +/- 4%, from hemorrhage 95 +/- 2%, from reoperation 62 +/- 11%, from valve failure 68 +/- 12%, and from all complications 47 +/- 8%. Among patients aged >60 years, the 18-year actuarial freedom from reoperation was 76 +/- 14%, and from valve failure 85 +/- 8%. CONCLUSION: With a low rate of valve-related events at 18 years, and an especially low rate of structural failure, the Perimount pericardial prosthesis is a reliable choice for patients with aortic calcified stenosis.
Authors:
Michel R Aupart; Alain Mirza; Yvon A Meurisse; Agnes L Sirinelli; Paul H Neville; Michel A Marchand
Related Documents :
12296924 - The medtronic intact bioprosthesis: clinical and hemodynamic performance over 13 years.
6705574 - Factors affecting survival in prosthetic valve endocarditis. review of the effectivenes...
3487294 - Experiences with 1643 porcine prosthetic valves in 1492 patients.
10709824 - Surgery for aortic regurgitation caused by behcet's disease: a clinical study of 11 pat...
3718034 - Bovine pericardium for correction of congenital heart defects.
17033854 - Is anterior release effective to increase flexibility in idiopathic thoracic scoliosis?...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The Journal of heart valve disease     Volume:  15     ISSN:  0966-8519     ISO Abbreviation:  J. Heart Valve Dis.     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-12-08     Completed Date:  2007-01-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9312096     Medline TA:  J Heart Valve Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  768-75; discussion 775-6     Citation Subset:  IM    
Affiliation:
Unit of Cardiac Surgery, A. Trousseau Hospital and F. Rabelais University, Tours, France. aupart@med.univ-tours.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Aortic Valve / surgery*
Aortic Valve Stenosis / mortality*,  surgery*
Bioprosthesis / statistics & numerical data*
Calcinosis / mortality*,  surgery*
Equipment Failure Analysis
Female
France / epidemiology
Heart Valve Prosthesis / statistics & numerical data*
Humans
Longitudinal Studies
Male
Middle Aged
Prosthesis Design
Risk Assessment / methods
Risk Factors
Survival Analysis
Survival Rate
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term follow up of the Biocor porcine bioprosthesis in the mitral position.
Next Document:  Long-term cardiac allograft valves after heart transplant are functionally and structurally preserve...